Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 4,244 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Seborrheic Dermatitis

NCT01703793
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Test Product 49778, Test Product 10156, Vehicle (placebo)
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Nov 4, 2026, 9:14 PM EST
Terminated Phase 4 Interventional Results available

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

NCT02170298
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration

NCT01709721
View directory record Official record
Conditions
Management of Chronic Pain
Interventions
Hydromorphone Hydrochloride, Programmable Implantable pump
Drug · Device
Lead sponsor
Piramal Critical Care, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 3 Interventional Results available

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

NCT01099449
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
Interventions
calcium gluconate, magnesium sulfate, placebo, oxaliplatin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
404
States / cities
Fairbanks, Alaska • Antioch, California • Fairfield, California + 278 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Nov 4, 2026, 9:14 PM EST
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07703514
View directory record Official record
Conditions
Influenza
Interventions
cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 9:14 PM EST
Active, not recruiting Phase 3 Interventional

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 3 Interventional Results available

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

NCT00810199
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], methotrexate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
21
States / cities
Santa Monica, California • Upland, California • Whittier, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Nov 4, 2026, 9:14 PM EST
Recruiting Phase 2 Interventional

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

NCT07428993
View directory record Official record
Conditions
Pediatric Osteosarcoma
Interventions
Cyclophosphamide, Fludarabine, Mesna, Apheresis, SJCARB7H3_41BBL infusion
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 4 Interventional Results available

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Semaglutide, Insulin Degludec, Insulin aspart
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

NCT03677648
View directory record Official record
Conditions
Crohn's Disease
Interventions
SHR0302, Placebos
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Clearwater, Florida • Lake Wales, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

NCT05154955
View directory record Official record
Conditions
Submental Fat
Interventions
10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Encino, California • San Diego, California • Rolling Meadows, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Nov 4, 2026, 9:14 PM EST
Terminated Phase 2 Interventional

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

NCT04387448
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 3 Interventional

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia

NCT00671255
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
102
States / cities
Columbiana, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 2 Interventional Results available

Cardiovascular Effects of COVID-19

NCT04365699
View directory record Official record
Conditions
COVID-19
Interventions
AT-001
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

NCT03949426
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 4 Interventional Results available

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

NCT00576732
View directory record Official record
Conditions
Autistic Disorder, Autism
Interventions
Placebo, Risperidone high dose, Risperidone low dose
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
5 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Dothan, Alabama • Phoenix, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Nov 4, 2026, 9:14 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

UCLA Magnesium Formulation Athlete Study

NCT07640685
View directory record Official record
Conditions
Athletic Performance, Recovery, Sleep
Interventions
Magnesium glycinate, Magnesium L-threonate, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 2 Interventional Results available

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

NCT01342484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo, BI1356 low dose, BI1356 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Antonio, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 2 Interventional Results available

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

NCT02713204
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
REGN910-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 2 Interventional

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

NCT02927184
View directory record Official record
Conditions
Hyperlipidemia, NAFLD
Interventions
VK2809, Placebo
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Nov 4, 2026, 9:14 PM EST
Completed Not applicable Interventional

Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery

NCT02144649
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
dietary intervention (tangerine tomato juice), dietary intervention (red tomato juice), questionnaire administration, Correlative studies
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Columbus, Ohio • Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously

NCT00333515
View directory record Official record
Conditions
Healthy Volunteers, Chemical Terrorism, Chemical Warfare
Interventions
Human Butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Nov 4, 2026, 9:14 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab, placebo for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
78
States / cities
Coronado, California • Irvine, California • La Jolla, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Nov 4, 2026, 9:14 PM EST
Completed Phase 3 Interventional Results available

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Nov 4, 2026, 9:14 PM EST